ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

UBT251

A development code. Also written as “UBT251 Injection 4.0 mg”, “UBT251 Injection 6.0 mg” and “UBT251 Injection 2.0 mg”.

In Novo Nordisk’s own words, UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Fatty Liver, led by 2 companies.

Drug pageUBT251: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 9, 202612 company-led studies, 12 open or runningLicense: The United Laboratories → Novo Nordisk, Mar 2025Next primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
The United Laboratories International88 open or runningphase 3since Jun 9, 2026Aug 13, 2025Dec 2026phase 1 · NCT07785934
Novo Nordiskits history only44 open or runningphase 2since Feb 1, 2026Feb 1, 2026Jan 14, 2027phase 2 · NCT07395687
  • Named in Novo Nordisk’s own pipeline as UBT251 (GLP-1/GIP/glucagon tri-agonist), phase 2, as of Nov 5, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of The United Laboratories International only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2025Novo Nordisk licensed it from The United LaboratoriesLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · The United Laboratories and Novo Nordisk (release)
  2. Aug 13, 2025First studies: 2 phase 2 studiesFirst studyNCT07145151, NCT07134335
  3. Jun 9, 20263 phase 3 studiesPhase 3 reachedNCT07648225, NCT07653477, NCT07659574
  4. Aug 11, 2026Phase 3 study in Sleep Apnea, ObstructiveNCT07767942 · 150 planned
  5. Aug 13, 2026Phase 1 study in ObesityNCT07785934 · 48 planned · China
  6. Sep 1, 2026Phase 3 study in Sleep Apnea, ObstructiveNCT07806851 · 150 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in ObesityNCT07785934
  2. Jun 4, 2027Primary completion: phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT07145151
  3. Sep 24, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07659574
  4. Sep 29, 2027Primary completion: phase 3 study in ObesityNCT07648225

TargetBeta

“UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon”company filing, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 8 The United Laboratories International leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07806851Sleep Apnea, Obstructive3Not yet recruitingMar 2029150
NCT07785934Obesity · China1RecruitingDec 202648
NCT07767942Sleep Apnea, Obstructive3Not yet recruitingSep 2028150
NCT07659574Diabetes Mellitus, Type 2 · China3RecruitingSep 24, 2027360
NCT07653477Diabetes Mellitus, Type 2 · China3RecruitingFeb 29, 2028956
NCT07648225Obesity · China3Active, not recruitingSep 29, 2027600
NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH) · China2RecruitingJun 4, 2027156
NCT07134335Obesity · China2RecruitingJul 11, 2030180

How it is read

Names in the registry

  • “UBT251”, 13 entries
  • “UBT251 Injection 4.0 mg”, 2 entries
  • “UBT251 Injection 6.0 mg”, 2 entries
  • “UBT251 Injection 2.0 mg”, 1 entry
  • “UBT251 Injection 2.0 mg group”, 1 entry

Codes read as this program: UBT251.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.